Dr. Israelsen’s Publications

Preprints & Submitted Manuscripts:

1. Cong Q, Brem EA, Zhang J, Alföldi J, Johnson J, Karlsson EK, Lindblad-Toh K, Malaney JL, Israelsen WJ. The meadow jumping mouse genome and transcriptome suggest mechanisms of hibernation. Preprint: bioRxiv (2020) doi: 10.1101/2020.11.02.365791. (LINK) (DATA)

2. Brem EA, McNulty AM, Israelsen WJ. Breeding and hibernation of captive meadow jumping mice (Zapus hudsonius). Preprint: bioRxiv (2020) doi:10.1101/2020.10.02.323386. (LINK)

3. Brem EA, Israelsen WJ. Courtship behavior of the meadow jumping mouse (Zapus hudsonius). Submitted. (2020) Accepted 1/5/2021.


Publications:

1. Liu VM, Howell AJ, Hosios AM, Li Z, Israelsen WJ, Vander Heiden MG. Cancer-associated mutations in human pyruvate kinase M2 impair enzyme activity. FEBS Letters, 2020 Feb; 594(4):646-664. (PDF)

2. Kallmyer NE, Shin HJ, Brem EA, Israelsen WJ, Reuel NF. Nesting box imager: Contact-free, real-time measurement of activity, surface body temperature, and respiratory rate applied to hibernating mouse models. PLoS Biology, 2019 Jul 24; 17(7), e3000406. (PDF)

3. Caron T J, Artim SC, Israelsen WJ, Holcombe HR, Fox JG, Bakthavatchalu V. Cutaneous Dermatophilosis in a Meadow Jumping Mouse (Zapus hudsonius). Comparative Medicine, 2018 Feb 1; 68(1):25–30. (PDF)

4. Lau AN, Israelsen WJ, Roper J, Sinnamon MJ, Georgeon L, Dayton T, Hillis AL, Yilmaz OH, Di Vizio D, Hung KE, Vander Heiden MG. PKM2 is not required for colon cancer initiated by APC loss. Cancer & Metabolism, 2017 Nov 30; 5(1):10. (PDF)

5. Qi W, Keenan HA, Li Q, Ishikado A, Kannt A, Sadowski T, Yorek MA, Wu IH, Lockhart S, Coppey LJ, Pfenninger A, Liew CW, Qiang G, Burkart AM, Hastings S, Pober D, Cahill C, Niewczas MA, Israelsen WJ, Tinsley L, Stillman IE, Amenta PS, Feener EP, Vander Heiden MG, Stanton RC, King GL. Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction. Nature Medicine, 2017 Jun; 23(6):753-762. (PDF)

6. Dayton, TL, Gocheva V, Miller KM, Israelsen WJ, Bhutkar A, Clish, CB, Davidson SM, Luengo A, Bronson RT, Jacks T, Vander Heiden MG. Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma. Genes & Development, 2016 May 1; 30(9):1020–1033. (PDF)

7. Israelsen WJ, Vander Heiden MG. Pyruvate kinase: Function, regulation and role in cancer. Seminars in Cell & Developmental Biology, 2015 Jul; 43:43-51. (PDF)

8. Palsson-McDermott EM, Curtis AM, Goel G, Lauterbach MA, Sheedy FJ, Gleeson LE, van den Bosch MW, Quinn SR, Domingo-Fernandez R, Johnston DG, Jiang JK, Israelsen WJ, Keane J, Thomas C, Clish C, Vander Heiden M, Xavier RJ, O'Neill LA. Pyruvate kinase M2 regulates Hif-1α activity and IL-1β induction and is a critical determinant of the warburg effect in LPS-activated macrophages. Cell Metabolism, 2015 Jan 6; 21(1):65-80. (PDF)

9. Lunt SY, Muralidhar V, Hosios AM, Israelsen WJ, Gui DY, Newhouse L, Ogrodzinski M, Hecht V, Xu K, Acevedo PN, Hollern DP, Bellinger G, Dayton TL, Christen S, Elia I, Dinh AT, Stephanopoulos G, Manalis SR, Yaffe MB, Andrechek ER, Fendt SM, Vander Heiden MG. Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation. Molecular Cell, 2015 Jan 8; 57(1):95-107. (PDF)

10. Wang YH, Israelsen WJ, Lee D, Yu VW, Jeanson NT, Clish CB, Cantley LC, Vander Heiden MG, Scadden DT. Cell-state-specific metabolic dependency in hematopoiesis and leukemogenesis. Cell, 2014 Sept 11; 158(6):1309-23. (PDF)

11. Israelsen WJ, Dayton TL, Davidson SM, Fiske BP, Hosios AM, Bellinger G, Li J, Yu Y, Sasaki M, Horner JW, Burga LN, Xie J, Jurczak MJ, Depinho RA, Clish CB, Jacks T, Kibbey RG, Wulf GM, Di Vizio D, Mills GB, Cantley LC, Vander Heiden MG. PKM2 Isoform-Specific Deletion Reveals a Differential Requirement for Pyruvate Kinase in Tumor Cells. Cell, 2013 Oct 10; 155(2):397-409. (PDF)

12. Anastasiou D, Yu Y, Israelsen WJ, Jiang J, Boxer MB, Hong BS, Tempel W, Dimov S, Shen M, Jha A, Yang H, Mattaini KR, Metallo CM, Fiske BP, Courtney KD, Malstrom S, Khan TM, Kung C, Skoumbourdis AP, Veith H, Southall N, Walsh MJ, Brimacombe KR, Leister W, Lunt SY, Johnson ZR, Yen KE, Kunii K, Davidson SM, Christofk HR, Austin CP, Inglese J, Harris MH, Asara JM, Stephanopoulos G, Salituro FG, Jin S, Dang L, Auld DS, Park H, Cantley LC, Thomas CJ, Vander Heiden MG. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nature Chemical Biology, 2012 Oct; 8(10):839-47. (PDF)

13. Vander Heiden MG, Lunt SY, Dayton TL, Fiske BP, Israelsen WJ, Mattaini K R, Vokes NI, Stephanopoulos G, Cantley LC, Metallo CM, Locasale JW. Metabolic Pathway Alterations that Support Cell Proliferation. Cold Spring Harbor Symposia on Quantitative Biology, 2011; 76:325–34. (PDF)

14. Walsh MJ, Brimacombe KR, Veith H, Bougie JM, Daniel T, Leister W, Cantley LC, Israelsen WJ, Vander Heiden MG, Shen M, Auld DS, Thomas CJ, Boxer MB. 2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorganic & Medicinal Chemistry Letters, 2011 Nov 1; 21(21):6322-7. (PDF)

15. Israelsen WJ, Vander Heiden, MG. ATP consumption promotes cancer metabolism. Cell, 2010 Nov 24; 143(5): 669-71. (PDF)